Pharming Group N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
19 sep 2007 - 17:35
Statutaire naam
Pharming Group N.V.
Titel
Pharming To Present At UBS Global Life Sciences Conference
Bericht
Leiden, The Netherlands, September 19, 2007. Biotech company Pharming Group NV (“Pharming”) (Euronext: PHARM) today announced that Pharming will present at the UBS Global Life Sciences (September 24-27, 2007) in New York.
Dr. Francis Pinto, Chief Executive Officer of Pharming, will present on Wednesday, September 26 at
2:00 pm Eastern Time. The presentation will be available on Pharming’s website after the meeting. The conference attendees include institutional investors from the United States, Europe and Asia-Pacific. For further information on the UBS Global Life Sciences Conference, please visit www.ibb.ubs.com.
Background on Pharming Group NV
Pharming Group NV is developing innovative products for the treatment of genetic disorders, ageing diseases, specialty products for surgical indications, intermediates for various applications and nutritional products. Pharming has two products in late stage development - Rhucin® (recombinant human C1 inhibitor) for hereditary angioedema (MAA under review by EMEA) and human lactoferrin for use in food products (GRAS notification under review by US FDA). The advanced technologies of the Company include innovative platforms for the production of protein therapeutics and technology and processes for the purification and formulation of these products, as well as technologies in the field of tissue repair (via its collaboration with NovaThera) and DNA repair (via its acquisition of DNage). Additional information is available on the Pharming website, http://www.pharming.com and on http://www.dnage.nl.
Datum laatste update: 24 februari 2026